Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity

The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about clinical experience with belantamab mafodotin, with a focus on strategies for managing ocular toxicity.

During this interview, Popat discussed clinical experience using belantamab mafodotin for patients with relapsed or refractory multiple myeloma (RRMM), highlighting its mechanism as a B-cell maturation antigen (BCMA)-directed antibody–drug conjugate and the practical management of associated ocular toxicities. Popat emphasized key considerations in patient selection, treatment sequencing, and individualized dosing strategies to optimize outcomes while minimizing adverse events. The discussion also covered real-world approaches to monitoring, dose adjustment, and maintaining long-term treatment benefit without compromising safety or efficacy.

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.